Product Images Olumiant
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Olumiant NDC 0002-4182 by Eli Lilly And Company, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
olumiant 1mg 30ct 066 02
olumiant 2mg 30ct 034 02
This is a prescription medication called Olumiant (baricitinib) in the form of 30 tablets. The recommended dosage is not given and further information can be obtained from the prescribing doctor. It is mandatory to dispense this medication with a medication guide. The NDC code for this medication is also provided.*
olumiant 4mg 30ct 073 00
Structural Formula - olumiant uspi chem v1
olumiant uspi f1 v3
This text is providing information related to the recommended adjustments in intrinsic factor PK ratio and 90%CL for different demographics such as weight, age, and ethnicity. Additionally, it suggests adjustment recommendations for individuals with renal or hepatic impairment. The text also includes a table with ratios relative to a reference.*
Figure 2 - olumiant uspi f2 v1
This appears to be a table showing recommendations for drug dosages and adjustments when coadministered with other drugs. The table includes PK ratios and 90% confidence limits for methotrexate, oral contraceptives containing ethinyl estradiol, and digoxin. However, the text is not particularly clear, so some details may be inaccurate.*
olumiant uspi f3 v3
This appears to be a table indicating the effects of various drugs and their potential interactions with each other. The table lists co-administered drugs, inhibitors, and inducers, and provides information on whether an adjustment in dosage is recommended or not. It also lists simulated versions of Ibuprofen and Diclofenac, Methotrexate, and Cyclosporine. The table shows the PK ratio and 90%Cl and a recommendation is provided for each drug-drug interaction.*
olumiant uspi f4 v2
The text shows a graph or chart comparing the percentage of responders to treatment with Olumiant, a 2 mg medication, versus a placebo. However, without more information or context, it is not possible to provide a specific description or interpretation of the data shown.*
olumiant uspi f5 v1
The text shows data from trial AA-1 and AA-2, with different doses of Olumiant compared to a placebo. The percentage of responders is shown for each treatment group. However, there is not enough information to determine what "responders" means, what condition was being treated, or what the purpose of the trials was.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.